Atezolizumab, an immune checkpoint inhibitor, caused precedent depressive symptoms related to limbic encephalitis

2021 ◽  
Author(s):  
Shuhei Wada ◽  
Kunihiro Iwamoto ◽  
Norio Ozaki
Keyword(s):  
Depressive Symptoms ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Limbic Encephalitis ◽  
Checkpoint Inhibitor

scholarly journals Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis

2018 ◽  
Vol 5 (2) ◽  
pp. e439 ◽  
Author(s):  
Andreas F. Hottinger ◽  
Rita de Micheli ◽  
Vanessa Guido ◽  
Alexandra Karampera ◽  
Patric Hagmann ◽  
...  
Keyword(s):  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Limbic Encephalitis ◽  
Checkpoint Inhibitor

scholarly journals Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma

2021 ◽  
pp. 724-728
Author(s):  
Rei Hashimoto ◽  
Etsuko Tanabe ◽  
Yoshihisa Otsuka ◽  
Yukihiro Yoneda ◽  
Yasufumi Kageyama
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Limbic Encephalitis ◽  
Checkpoint Inhibitor ◽  
Antibody Test ◽  
Pleural Mesothelioma ◽  
Paraneoplastic Encephalitis ◽  
Neurological Improvement ◽  
Checkpoint Inhibitor Therapy

Neurological adverse events of immune checkpoint inhibitor (ICI) therapy mostly develop within 3 months after initiation of ICI treatment. An 82-year-old male with malignant pleural mesothelioma developed anti-Ma2-associated limbic encephalitis at a delay of 18 months after the start of nivolumab therapy (3 months after termination of a 15-month course of ICI treatment). Immunotherapy with steroids and immunoglobulins resulted in moderate neurological improvement. Over the next year, malignant pleural mesothelioma gradually worsened, while the anti-Ma2 antibody test remained positive. Anti-Ma2 paraneoplastic encephalitis may occur after a delay following the discontinuation of ICI therapy.

759 IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED CELIAC DISEASE

2020 ◽  
Vol 158 (6) ◽  
pp. S-156
Author(s):  
Yousef R. Badran ◽  
Angela Shih ◽  
Donna Leet ◽  
Alexandra Coromilas ◽  
Jonathan Chen ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor

Abstract #514 Secondary Adrenal Insufficiency Due to the Immune Checkpoint Inhibitor Pembrolizumab

2019 ◽  
Vol 25 ◽  
pp. 256
Author(s):  
Mohammad Ansari ◽  
Ula Tarabichi ◽  
Hadoun Jabri ◽  
Qiang Nai ◽  
Anis Rehman ◽  
...  
Keyword(s):  
Adrenal Insufficiency ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Secondary Adrenal Insufficiency

A Systematic Review of Cases of Diabetes Mellitus following Immune Checkpoint Inhibitor Therapy for Cancer

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 204-LB ◽  
Author(s):  
KARA R. MIZOKAMI-STOUT ◽  
ROMA GIANCHANDANI ◽  
MARK MACEACHERN ◽  
RAVI M. IYENGAR ◽  
SARAH YENTZ ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Systematic Review ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Inhibitor Therapy ◽  
Checkpoint Inhibitor Therapy

1672-P: Characterization of Immune Checkpoint Inhibitor–Mediated Hyperglycemia: Beyond Insulin-Dependent Diabetes

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1672-P
Author(s):  
AMANDA LEITER ◽  
EMILY CARROLL ◽  
DANIELLE C. BROOKS ◽  
JENNIFER BEN SHIMOL ◽  
ELLIOT EISENBERG ◽  
...  
Keyword(s):  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Insulin Dependent Diabetes ◽  
Insulin Dependent

1669-P: Immune Checkpoint Inhibitor Induced Diabetes and Diabetic Ketoacidosis

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1669-P
Author(s):  
SHAHZEENA HAFEEZ ◽  
PRIYATHAMA VELLANKI ◽  
MINZHI XING ◽  
GUILLERMO E. UMPIERREZ
Keyword(s):  
Diabetic Ketoacidosis ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor
Sign in / Sign up

Export Citation Format

Share Document